Deutsche Bank (DB) Analysts Reiterate a "Buy" Rating on Biogen Idec (BIIB) LocalizedUSA It includes BG-12, Daclizumab, Fampridine, GA101, Humanized Anti-CD20 MAb (ocrelizumab), Lixiavaptan, Long-Acting rFactor IX and PEGylated interferon beta-1a. Shares of Biogen Idec opened at 102.64 on Wednesday. Biogen Idec has a 52 week low of $57.58 ... |
